DMT
DMT is a naturally occurring psychedelic of the tryptamine class, found widely throughout the plant and animal kingdoms, including in trace amounts in humans.citation needed Richard Manske first synthesized it in 1931, and South American entheogenic traditions have used it for millennia. When vaporized, DMT produces an exceptionally intense but brief psychedelic experience. It can also be taken orally alongside a monoamine oxidase inhibitor, as in traditional ayahuasca preparations.1
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
These dosage values assume complete vaporization efficiency. In practice, most vaporization techniques do not achieve full efficiency, so actual doses may need adjustment. The probability of a breakthrough experience increases at higher doses. Caution is advised when approaching higher dosage ranges. Start lower to reduce risk of taking too much.
Duration
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Effects vary widely by individual, dose, and context.
Physical
Cognitive
The head space of DMT is described by most as extremely sober and clear headed in its style when compared to other commonly used psychedelics such as LSD, psilocin or even ayahuasca. It contains a limited amount of typical cognitive effects. DMT in its smokeable form is perhaps the least psychologically intoxicating psychedelic, leading many people to describe it not as a drug induced trip but a genuine experience that is actually happening to them.
Progressive Stages
The first step of a DMT trip is the come up that leads onto breaking through. A person notices an extremely distinct set of visual enhancements, most notably an increase in visual acuity and colour intensity. This is followed by a sudden onset of high level geometry, the body high, and the feeling of your body being pleasantly tugged in all directions at once from the inside. This is often accompanied by a soft crackling sound and an extended tone that quickly increases in volume and pitch.
Almost immediately after taking off, trippers often find themselves spending a brief amount of time in what feels like a psychedelic 'waiting room' or 'loading screen'. This can take any form but generally takes the shape of a tunnel or space comprised of fast moving geometry that lasts approximately 10-20 seconds and feels distinctively different from the main bulk of the trip.
Once the waiting period is over, the user will feel that they have broken through onto the other side. This is visiting an alternate reality that feels so real it seems to be better defined than real life, usually with a single or multiple external autonomous entities in front of your line of sight. These entities appear to have been waiting for your arrival, usually completely unsurprised by the tripper's sudden appearance.
The final stage is experienced as the sensation of being pulled further and further away from the scenario in which you were placed as the entities often wave goodbye and encourage you to come back when you next get the chance.
Visual
Geometry
The geometry present with smokeable DMT is often considered to be the most profoundly intricate and complex set of visual geometry found within the entirety of the psychedelic experience. In comparison to orally active DMT (ayahuasca) they are significantly more digital in appearance and contain a colour scheme which is similar to LSD but a structured style that is closer to high dose psilocin.
Hallucinatory States
DMT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of any other commonly used psychedelic.
Auditory
See also: Psychedelic Intensity Scale, DMT guide, Effects of psychedelics (visual, cognitive, miscellaneous)
Reagent Testing
Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.
Pharmacology
Pharmacodynamics
DMT acts primarily through agonism at the serotonin 5-HT2A receptor, which is considered the principal mediator of its psychedelic effects.citation needed It has been characterized as a partial and biased agonist at this site, activating the Gq signaling pathway without significantly recruiting β-arrestin2. DMT also acts as an agonist at 5-HT1A and 5-HT2C receptors and shows broad, non-selective binding across numerous additional serotonin subtypes.2 It is additionally a potent serotonin releasing agent and functions as an agonist at sigma-1 and trace amine-associated receptor 1 (TAAR1), with further affinity demonstrated at dopamine D1, adrenergic, and imidazoline-1 receptors.citation needed
Pharmacokinetics
DMT is rapidly metabolized by monoamine oxidase A (MAO-A), rendering it orally inactive unless combined with a monoamine oxidase inhibitor.citation needed The primary metabolic product is indole-3-acetic acid, with DMT-N-oxide as a notable secondary metabolite. Additional pathways include N-dealkylation and cyclization to β-carbolines. To a lesser extent, CYP2D6 and CYP2C19 contribute to hepatic metabolism; when smoked, a more substantial fraction (possibly 10–20%) is processed through these enzymes. Following intravenous administration, DMT has a plasma half-life of approximately 9–12 minutes and can become undetectable in blood within about one hour. DMT readily crosses the blood-brain barrier and has been observed to accumulate in brain tissue following peripheral administration in animal models.2
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Serotonergic psychedelics (limited; research from the 1970s found LSD-tolerant individuals showed minimal cross-tolerance to DMT)
Harm Potential
Addiction & Dependence
Psychological
Extremely LowDMT is considered non-addictive with low abuse potential.citation needed Many users report a self-regulating quality to the substance, and studies examining substance use disorder found almost no hallucinogens produced dependence.
Physical
Extremely LowNo physical dependence or withdrawal syndrome has been documented with DMT use.citation needed The physiological dependence potential appears minimal when used infrequently.
Toxicity
Psychosis Risk
DMT can trigger psychological reactions including intense fear, paranoia, anxiety, panic attacks, and substance-induced psychosis, particularly in predisposed individuals.citation needed Latent psychoses may be triggered, and permanent disturbances in self- and reality-recognition are possible in vulnerable populations. Case reports describe temporary psychotic episodes that typically resolved within weeks, though individuals with personal or family history of psychotic illness appear at elevated risk.
Seizure Risk
Seizure risk from DMT alone appears minimal; documented seizure concerns primarily involve drug combinations, particularly with lithium or tramadol.citation needed
History & Culture
Traditional Use
DMT has been used as an entheogen in South America for thousands of years,citation needed primarily in the form of ayahuasca brews and snuffs. Archaeological evidence suggests snuff use dating back several millennia, though DMT typically served as a minor constituent in these…
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
International
UN Convention on Psychotropic Substances 1971 (Schedule I)
By Country
References
Source Pages
Citations
- Klemens Egger, Helena D. Aicher, Paul Cumming, & Milan Scheidegger. (n.d.). Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors. Cellular and Molecular Life Sciences, 81(1), Article 395. https://doi.org/10.1007/s00018-024-05353-61
- Carbonaro TM, & Gatch MB. (September 2016). Neuropharmacology of N,N-dimethyltryptamine. Brain Research Bulletin, 126, 74–88. https://doi.org/10.1016/j.brainresbull.2016.04.0161234
- Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, & Knowles R. (September 2023). The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. Journal of Psychopharmacology, 37(9), 876–890. https://doi.org/10.1177/026988112311908651
- Szara, Stephen. Center for the Study of the History of Neuropsychopharmacology (2022-03-11). https://cshn.semel.ucla.edu/2022/03/11/szara-stephen/1
- Primary legal source. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L00633/asmade/2026-05-28/text/original/epub/OEBPS/document_1/document_1.html1
- Primary legal source. ris.bka.gv.at (n.d.). https://ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Anlage=5&Artikel=&FassungVom=2026-02-05&Gesetzesnummer=10011053&Paragraf=&ShowPrintPreview=True&Uebergangsrecht=1
- Primary legal source. afmps.be (n.d.). https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf1
- Primary legal source. ejustice.just.fgov.be (n.d.). https://www.ejustice.just.fgov.be/cgi/article_body.pl?language=fr&caller=summary&pub_date=17-09-26&numac=20170312311
- Primary legal source. bvsms.saude.gov.br (n.d.). https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2010/rdc0021_17_06_2010.html1
- Primary legal source. pesquisa.in.gov.br (n.d.). https://pesquisa.in.gov.br/imprensa/servlet/INPDFViewer?captchafield=firstAccess&data=26%2F01%2F2010&jornal=1&pagina=571
Further Reading
Chacruna - DMT and serotonin syndrome risks
dos Santos et al. - Ayahuasca risks review (2016)
Mind Foundation - Psychedelic-Antidepressant Interactions
Nichols DE - Psychedelics review (2016)
PMC: Drug-drug interactions involving classic psychedelics
PubChem: N,N-Dimethyltryptamine (CID 6089)
Spiers et al. - Continuous DMT infusion study (2024)
Spirit Pharmacist - Healing States or Serotonin Toxicity
Strassman RJ - Dose-response study in humans (1994)
Timmermann et al. - DMT models near-death experience (2018)
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
11 July 2026
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the DMT article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
